You are here: Industry Insights > BRCA

News List

Did Your Gene Screen Turn Up Dangerous DNA? Study Finds Real Risk Is Low drugs.com
January 27, 2022
Most gene variants that have been labeled "pathogenic" may make only a small difference...
Lynparza Granted Priority Review in the US for Breast Cancer AmericanPharmaceuticalReview
December 01, 2021
AstraZeneca’s supplemental New Drug Application (sNDA) for Lynparza (olaparib) has been accepted and granted Priority Review in the US for the adjuvant treatment of patients with BRCA-mutated (BRCAm) HER2-negative high-risk early breast cancer who have...
Researchers identify new drug class with potential in BRCA-mutated tumours pharmatimes
June 21, 2021
Researchers from the The Institute of Cancer Research, London and Artios have identified a new class of drugs – POLQ inhibitors – which could have potential for patients with BRCA-mutated tumours.
Lynparza approved by FDA to treat germline BRCA-mutated metastatic pancreatic cancer europeanpharmaceuticalreview
January 03, 2020
The FDA has approved Lynparza as a first-line treatment after it reduced the risk of disease progression or death by 47 percent in patients.
USPSTF Recommends Genetic Counseling for High BRCA Risk drugs
August 21, 2019
The U.S. Preventive Services Task Force (USPSTF) recommends that women who are at increased risk for BRCA1/2 mutations should undergo genetic counseling, and if indicated...
Lynparza has been approved for BRCA-mutated advanced ovarian cancer europeanpharmaceuticalreview
June 24, 2019
BRCA-mutated advanced ovarian cancer treatment has been approved by the European Commission.
ASCO: Olaparib Beats Placebo for BRCA-Related Pancreatic Cancer drugs
June 05, 2019
Olaparib Beats Placebo for BRCA-Related Pancreatic Cancer.
NICE says no to expanding use of AZ’ Lynparza pharmatimes
November 12, 2018
The National Institute for Health and Care Excellence has ruled against expanding use of AstraZeneca’s Lynparza to a wider patient population with ovarian cancer.
EU regulators widen Lynparza’s reach pharmatimes
July 09, 2018
European regulators have approved a tablet formulation and new dosing regimen for AstraZeneca and MSD’s Lynparza to treat a wider range of patients with ovarian cancer.
Ovarian cancer drug shows promise in pancreatic cancer patients with BRCA mutation worldpharmanews
May 23, 2018
A targeted therapy that has shown its power in fighting ovarian cancer in women including those with BRCA1 and BRCA2 mutations may also help patients with aggressive pancreatic cancer who harbor these mutations and have few or no other treatment options.

Previous page 1 2 Next page